Zuco V - Search Results

1

Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.

Alessandrini I, Percio S, Naghshineh E, Zuco V, Stacchiotti S, Gronchi A, Pasquali S, Zaffaroni N, Folini M. Alessandrini I, et al. Among authors: zuco v. Cancers (Basel). 2022 May 25;14(11):2624. doi: 10.3390/cancers14112624. Cancers (Basel). 2022. PMID: 35681604 Free PMC article.

2

Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.

Zuco V, De Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F. Zuco V, et al. PLoS One. 2011;6(12):e29085. doi: 10.1371/journal.pone.0029085. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194993 Free PMC article.

3

Targeting DNA topoisomerase I with non-camptothecin poisons.

Beretta GL, Zuco V, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zuco v. Curr Med Chem. 2012;19(8):1238-57. doi: 10.2174/092986712799320529. Curr Med Chem. 2012. PMID: 22204335 Review.

4

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F. Cassinelli G, et al. Among authors: zuco v. Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13. Biochem Pharmacol. 2012. PMID: 22525722

5

Namitecan: a hydrophilic camptothecin with a promising preclinical profile.

Beretta GL, Zuco V, De Cesare M, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zuco v. Curr Med Chem. 2012;19(21):3488-501. doi: 10.2174/092986712801323252. Curr Med Chem. 2012. PMID: 22680917 Review.

6

Drug combinations with proteasome inhibitors in antitumor therapy.

Gatti L, Zuco V, Zaffaroni N, Perego P. Gatti L, et al. Among authors: zuco v. Curr Pharm Des. 2013;19(22):4094-114. doi: 10.2174/1381612811319220015. Curr Pharm Des. 2013. PMID: 23181571 Review.

7

Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.

Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Cassinelli G, et al. Among authors: zuco v. Curr Med Chem. 2013;20(15):1923-45. doi: 10.2174/09298673113209990106. Curr Med Chem. 2013. PMID: 23410153 Review.

8

Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.

De Cesare M, Lauricella C, Veronese SM, Cominetti D, Pisano C, Zunino F, Zaffaroni N, Zuco V. De Cesare M, et al. Among authors: zuco v. Clin Cancer Res. 2014 Feb 15;20(4):995-1006. doi: 10.1158/1078-0432.CCR-13-1684. Epub 2013 Dec 10. Clin Cancer Res. 2014. PMID: 24327272

9

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P. Zuco V, et al. Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16. Biochem Pharmacol. 2015. PMID: 25600908

10

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.

Zuco V, De Cesare M, Zaffaroni N, Lanzi C, Cassinelli G. Zuco V, et al. Oncotarget. 2015 Apr 20;6(11):8736-49. doi: 10.18632/oncotarget.3538. Oncotarget. 2015. PMID: 25826089 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page